Throughout the year, and especially during Childhood Cancer Awareness Month every September, Cmed and Aixial recognize the devastating impact cancers have on children around the world and the therapeutic research and treatments that are still yet needed.
According to the Children’s Cancer Research Fund, each year, more than 15,000 kids and young adults are diagnosed with cancer—that’s about 43 per day. While a cancer diagnosis is difficult at any age, a child diagnosed may not fully understand the way they’re feeling, the need for various treatments (and dealing with their potential side effects), or the multitude of trips to the hospital. This can cause a range of emotions, as well as, exhaustion for not only the patient, but for the loved ones caring for them and their important medical care teams, made up of doctors, nurses, oncologists, radiologists, and more.
These are compelling reasons why the clinical operations and data science experts at Cmed and Aixial wish to partner with biotech sponsors to find advancements in treatments that can make a positive and lasting impact in the fight against pediatric cancers.
At Cmed, we’ve proudly been working on pediatric trials, in multiple areas which include oncology and rare disease, over the last 20 years (over 60 in total). We have experienced pediatric and oncology physicians on staff to support trial needs, as well as a team of oncology trial experts who can make a real difference when it comes to these types of trials. Our work also extends to advanced research, including ATIMPs and advanced antibodies (bispecific, trispecific, ADCs, vaccines).
While treatment outcomes have largely improved for pediatric cancers, with Cancer.org stating that 84% of children with cancer now survive 5 years or more, the work is still not done. So together, let’s spread the word about the importance of pediatric cancer research and partner to end this terrible fight of our youngest patients around the globe.